What is BioMarin Pharmaceutical Inc.'s current stock price?

As of November 27, 2025, BioMarin Pharmaceutical Inc. (BM8.DE) closed at €61.96 on the XETRA exchange in Germany, reflecting a decrease of 1.71% from the previous day.

How is BioMarin performing financially?

BioMarin's PE ratio stands at 88.51, with a market cap of approximately €11.76 billion. The company exhibits strong liquidity with a current ratio of 5.33, although the high PE ratio suggests it might be overvalued.

What are BioMarin's growth prospects?

BioMarin has shown robust revenue growth of 17.97% in the fiscal year 2024. Analyst forecasts predict a price target of €66.56 over the next year, driven by strategic developments in genetic therapies.

How does BioMarin compare within the Biotechnology sector?

BioMarin operates in the competitive Biotechnology sector, facing regulatory and market challenges. However, its innovative product pipeline provides potential for future performance, aligning with industry growth trends.

What factors influence BioMarin's stock price?

Stock prices can fluctuate based on market conditions, economic factors, and company-specific events. BioMarin's upcoming product approvals and financial performance will be key to its stock valuation.

DE Stocks

BioMarin Pharmaceutical Inc. (BM8.DE) Stock Analysis: Can This Biotech Rebound?

ByHuzaifa Zahoor November 27, 2025November 27, 2025

BioMarin Pharmaceutical Inc. (BM8.DE), listed on Germany’s XETRA, witnessed a decline of 1.71% on November 27, 2025, with its share price closing at €61.96. As the stock hovers above its year low, we dive into the current performance, financial metrics, and future prospects of this biotech giant.